Soleno Therapeutics, Inc.

The European Medicines Agency has begun reviewing a new batch of products for potential pan-EU marketing approval, including LIB Therapeutics’ lerodalcibep for treating primary hypercholesterolemia or

Stock market turmoil due to macroeconomic uncertainty and biopharmaceutical industry-specific concerns have made it more difficult for publicly traded drug developers to pursue follow-on public offeri

Soleno Therapeutics has gained US approval for Vykat XR, making it the first ever drug to treat hyperphagia, an intense, persistent hunger experienced by people with the rare genetic disorder Prader-W

The European Medicines Agency was this week deciding whether the planned EU marketing authorization applications (MAAs) for three investigational products deserved accelerated assessments – apitegroma